Cargando…
Cost effectiveness and cost utility of the noncoding blood glucose meter CONTOUR(®) TS
AIMS: This study assessed the cost efficacy and cost utility of the automatic blood glucose meter CONTOUR(®) TS from the public payer (National Health Fund [NHF]) and payer (patient and NHF) perspectives over a 26-year analysis horizon. METHODS: Clinical effectiveness data were obtained from prior c...
Autores principales: | Holko, Przemyslaw, Kawalec, Pawal |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064416/ https://www.ncbi.nlm.nih.gov/pubmed/21448325 http://dx.doi.org/10.2147/DMSO.S9395 |
Ejemplares similares
-
Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018) -
Cost-utility analysis of Ruconest(®) (conestat alfa) compared to Berinert(®) P (human C1 esterase inhibitor) in the treatment of acute, life-threatening angioedema attacks in patients with hereditary angioedema
por: Kawalec, Paweł, et al.
Publicado: (2013) -
Health-Related Quality of Life Impairment and Indirect Cost of Crohn’s Disease: A Self-Report Study in Poland
por: Holko, Przemysław, et al.
Publicado: (2016) -
Indirect Costs of Inflammatory Bowel Diseases: A Comparison of Patient-Reported Outcomes Across 12 European Countries
por: Holko, Przemysław, et al.
Publicado: (2022) -
A Comment on Craig et al.: ‘‘Retigabine for the Adjunctive Treatment of Adults with Partial-Onset Seizures in Epilepsy with and without Secondary Generalization: A NICE Single Technology Appraisal’’
por: Holko, Przemysław, et al.
Publicado: (2013)